<SEC-DOCUMENT>0001193125-16-589213.txt : 20160513
<SEC-HEADER>0001193125-16-589213.hdr.sgml : 20160513
<ACCEPTANCE-DATETIME>20160512200609
ACCESSION NUMBER:		0001193125-16-589213
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160512
FILED AS OF DATE:		20160513
DATE AS OF CHANGE:		20160512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prima BioMed Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		161645533

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d189237d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13A-16</FONT> OR
<FONT STYLE="white-space:nowrap">15D-16</FONT> UNDER THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated May 12, 2016 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">001-35428</FONT> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>RIMA</SMALL> B<SMALL>IO</SMALL>M<SMALL>ED</SMALL> L<SMALL>TD</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of Registrant&#146;s Name) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 12, 95 Pitt Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by
check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;</FONT><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;</FONT><FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (1):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by
Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;
&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): Not applicable. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: May 12, 2016 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>Prima BioMed Ltd</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:75.45pt; font-size:8pt; font-family:Times New Roman"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">PRIMA BIOMED ENTERS INTO SALE AND LICENSING AGREEMENT WITH SYDYS TO ADVANCE CVAC<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>
PROGRAM</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d189237dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g189237g34j23.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12&nbsp;May 2016 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRIMA BIOMED ENTERS INTO
SALE AND LICENSING AGREEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WITH SYDYS TO ADVANCE CVAC<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> PROGRAM </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Sydys Licenses Clinical-Stage Immuno-oncology Assets in &#145;spin out&#146; transaction</I></B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Potential for over A$400M in milestones and royalties</I></B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Prima to receive 9.9% equity in Sydys</I></B> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SYDNEY, AUSTRALIA and SEATTLE, WASHINGTON - Prima BioMed
Ltd (ASX: PRR; NASDAQ: PBMD) (&#147;Prima&#148;) and U.S.-based Sydys Corporation, Inc. (OTC: SYYC) (&#147;Sydys&#148;), today announced an agreement through which Sydys will license Prima&#146;s CVac&#153; immuno-oncology program and oversee its
future development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sydys Corporation (www.sydyscorp.com) is a publicly traded New York company that has been repurposed as a clinical stage
biotechnology company in order to develop the CVac assets. Under the terms of the agreement, Sydys will license Prima&#146;s CVac related assets, including manufacturing protocols, clinical data from Phase I and Phase II trials, patents and
know-how.&nbsp;Prima will also sell certain assets including some equipment and inventory to Sydys.&nbsp;Dr Sharron Gargosky, the former Chief Technical Officer of Prima who has overseen the development of CVac since 2010, will also transition to
Sydys as a consultant to continue the development of CVac. Marc Voigt, Prima&#146;s CEO, will join the Sydys Board of Directors soon after closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
this spin out transaction Prima will receive a 9.9% equity stake in Sydys at the time of closing as consideration for the assets being transferred. Given the significant capital requirements for conducting clinical trials, no upfront payment will be
received however should CVac be successfully commercialized, Prima could receive over A$400 million (US$293 million) in development, regulatory and commercial milestone payments payable for achievement of set commercial sales targets, in addition to
low single digit royalties on sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marc Voigt, Prima&#146;s CEO, commented: &#147;Following extensive discussions with a number of third parties, we
have reached what we consider to be an entrepreneurial solution which we believe best positions CVac for clinical success and, hopefully, commercialization. Importantly, this partnership continues the CVac program development without further
resource commitment from Prima, while providing the potential for considerable future milestone and royalty payments over time. The ongoing development will be contingent on further successful capital raising for subsequent trials but we are
confident that the Sydys team has the ability and connections in the US to undertake this program.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Experienced biotech entrepreneur Joseph
Hernandez, the newly appointed Executive Chairman of Sydys Corporation, added: &#147;We believe that the CVac program has tremendous potential, supported by encouraging Phase I and II data in ovarian cancer patients. Studies conducted to
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
date have reinforced CVac&#146;s strong safety profile and demonstrated meaningful improvements in both overall survival and progression-free survival compared to standard-of-care. We look
forward to further evaluating the efficacy of CVac with the goal of bringing the treatment to this underserved patient population.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CVac
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CVac therapy is a personalized immunocellular therapeutic that has been investigated for the treatment of epithelial cancers. CVac stimulates the
patient&#146;s own immune system to target and destroy tumours. It has been investigated in multiple Phase I and Phase II studies with positive results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development highlights for CVac include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Completion of a randomized Phase II trial that identified epithelial ovarian cancer patients in second remission (CR2) as the target CVac patient population </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CR2 patients receiving CVac have experienced a clinically meaningful improvement in overall survival (OS), as indicated by final data analysis. These data demonstrated median OS of standard of care patients of 25.53
months, while the CVac arm had not reached a median at 42 months (HR=0.17) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CR2 patients receiving CVac experienced a clinically significant improvement in progression free survival (PFS) of greater than 12.91 months, compared with a PFS of 4.94 months (HR=0.32) for the standard-of-care
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CR2 for ovarian cancer is a high unmet medical need; CVac has obtained Orphan Designation for the treatment of ovarian cancer by both the
FDA and EMA and Fast Track Designation with the FDA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Prima BioMed </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is a globally active biotechnology company that is striving to become a leader in the development of immunotherapeutic products for the treatment
of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima&#146;s current lead product is IMP321, based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune
response. IMP321, which is a soluble LAG-3Ig fusion protein, is an APC activator boosting T cell responses.&nbsp;IMP321 is currently in a Phase II clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov
identifier <U>NCT 02614833</U>) and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier <U>NCT 02676869</U>). A number of additional LAG-3 products including antibodies for immune response
modulation in autoimmunity and cancer are being developed by large pharmaceutical partners. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Prima BioMed Ltd</B>, Level 12, 95 Pitt Street, Sydney NSW 2000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Phone: +61 2 8315 7003 Fax: +61 2 8569 1880 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">www.primabiomed.com.au ABN: 90 009 237 889 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information
please visit www.primabiomed.com.au </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Sydys Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Post completion of the transaction, Sydys Corp will be a globally active, publicly traded biotechnology company developing immuno-oncology products including
an autologous dendritic cell immunotherapy that recently completed Phase II trials for ovarian cancer. That trial generated clinically meaningful progression free survival (PFS) and overall survival (OS) data. More information is available at
www.sydyscorp.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For further information please contact: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors:</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthew Beck, The Trout Group LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (646) 378-2933; mbeck@troutgroup.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian
Investors/Media:</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr Matthew Gregorowski, Citadel-MAGNUS </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 2 8234 0100; <U>mgregorowski@citadelmagnus.com</U> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Prima BioMed Ltd</B>, Level 12, 95 Pitt Street, Sydney NSW 2000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Phone: +61 2 8315 7003 Fax: +61 2 8569 1880 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">www.primabiomed.com.au ABN: 90 009 237 889 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g189237g34j23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189237g34j23.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7X!^'!_9AU?]FCQYK\+6-YXFO;B+6BXPRI<,/*WG_KG(I_.MO]L;PK?>.O\
M@H%X5T+0=:N?#U]JMG80V^JVP)DM6(?#K@CG\:^OOVNOV8;C]HOP'X>T/PYJ
M=IH=YX=U..ZMI[B)G78J%2GR\CL?PKR[X]?L0^._BC\7M%\?^#O'&F^'M5T?
M2K2VCF:"1I%N(4PTBD=B2<4".Y^"'[*_COX6?$*T\0>+/C)XD\9:=;PRQOI5
M\C".0NN QRYY!YZ5\X?&7/\ P]+\'_\ 7;3_ /T4:]U^&?[.W[0'AKQ]H>J^
M./C5_;^@V-VLM_IGE./M48!RG(^E8?[0_P"Q#XV^*?Q]_P"%E_#_ ,;:=X9N
MX((%M"\#M+"\:[=P(XH ]H_:^\=^'O G[/\ XQE\830"/4=,FL[6VD(+7$TB
ME455ZGD@^V*\._X)0:1>6'P(UR[O(7CM]0UYFMG88$@6-58CVSQ^%8MY_P $
MX_&GQ.U^QU#]H'XO:AXF@LR/W$,+$E,Y*@L<+GU S7VIX#\":)\-/">G^&_!
MEC'IVCZ7%Y=O G.!G))/<DDDGWI/8#H****@ HHHH **** /F_1_VYO!5ZP&
MJZ?K6G9[F,2C]#78Z=^U?\,]0 QX@6W+?PSP.A'Z5^<6.>.M. XYKX^.>XE;
MV?R/W>MX;Y1/X'./S3_-'Z>V7QX^'^H$"V\5Z.2>S3A?YUT]AXLT75%#:=JV
MFW*GH8KI&_K7Y-E03T%3VUQ-;-FWGFA([I(5_E71'B"?VH+[SRZOAAAW_#Q#
M7JD_U1^MZ3H_*LA'8A@<T_<#W%?D^GB;6$ ":OJBCMB\D_QJ_IGQ!\2Z3+YE
MEKFIJW^U<N_Z$UM'B&+WI_C_ , X*GA?62;AB4W_ (;?JS]4J*_./2/VGOB/
MHZ!;?7O.1>BSVZ/_ $KJK/\ ;3\?VP474>C76.[6Q4G\C73'/<,]TT>56\.,
MWA\,H2^;7YH^\J*^*[+]NCQ'&P^W^'M)F7OLE=376:9^W7IKJHU?PS>Q$_>,
M%PK#]:WCF^#?VK?)GFU>!\\I_P#+F_HT_P!3ZHHKY]LOVU/ UP!]HMM9MB>N
M;<-C\C6W9?M:?#F]<!M8N;;)_P"6UHRC\ZWCC\++_EXOO/,J\.9M35Y8>7W-
M_D>ST5PFG?'+P'JBJ;+Q1I3%NSR[#^M;]OXW\/W8'V76M*E)Z;;M#_6MXUJ4
MMI+[SSZF!Q5/XZ<EZIHW**J0:I:W/-O<VTH/39*K?R-60^1E>:T6NQS--;CJ
M*9YGJ.:<#3$+1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRF?'F>6?[C$9QV/2N]HH3 \]L_@_IUQ\5I/B%XC"WVO0V/V#3%(S'I\&26*
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MTUXQC/S?V:X][?\ ^O5F/]JGQ.F-]AI3^OR,/ZUXVS<]*BD]::S+%K[;,_\
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M2XI:=[ ,8?+S2 4I.>*0=Z94=Q:***"S]@Z***_2#^/PHHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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A'HMY<#_VI1117G/#T;_ ON1]'2S?,.1?OY_^!2_S/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
